MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.68 -0.60%

-$0.09 today

Market cap
$176.61M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.16M

Average 0.09M

MDWD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

MediWound Ltd.NASDAQ: MDWD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $5.19M rose 79.7% year over year, ahead of the +61.4% change in trailing-twelve-month research & development. Sequentially, it rose 15.8% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.

Context

  • Research & development amounted to 84.4% of revenue in FY2025, up 40.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +79.7% holds above the trailing-twelve-month pace of +61.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.19M+15.8% QoQ
Last fiscal yearDec 2025
$14.32M+61.3% YoY
LTMMar 2026
$16.62M+61.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+79.7%——
1 year+61.3%——
3-year CAGR+12.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
14.32M USD
Year-over-year change
+61.3%
4-year CAGR
+8.7%

Research & Development vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +61.4% is the 3rd highest of 9, against a peer median of +35.0%.
  • Research & development amounts to 114.8% of revenue for MDWD, versus a peer median of 1024.9%.
MDWD Competitors
Research & Development for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$62.82M USD+25.5%-7.1%3539.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M USD-50.0%-40.2%104.5%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$57.75M USD+141.5%+89.7%—
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M USD+41.8%+36.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M USD+72.6%+29.4%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M USD+47.2%-19.1%—
MDWDMediWound Ltd.LTM Mar 2026$16.62M USD+61.4%+12.0%114.8%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$3.93M USD———
Peer median (excluding MDWD) —+35.0%+20.4%1024.9%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.76M26.5M18.69M20.22M16.96M
Cost of Revenue14.99M13.33M15.11M17.59M13.71M
Gross Profit8.77M13.17M3.58M2.63M3.25M
Gross Margin36.9%49.7%19.1%13.0%19.2%
Research & Development10.26M10.18M7.47M8.88M14.32M
Selling, General & Admin9.45M10.37M11.38M12.91M13.93M
Operating Expenses19.99M20.83M19.08M22.02M28.53M
Depreciation & Amortization1.24M1.27M1.3M1.48M1.86M
EBITDA(11.38M)(18.25M)(4.8M)(27.93M)(21.47M)
EBITDA Margin-47.9%-68.9%-25.7%-138.1%-126.6%
Operating Income(11.22M)(7.66M)(15.5M)(19.38M)(25.28M)
Operating Margin-47.2%-28.9%-83.0%-95.8%-149.1%
Interest Income11K270K2.34M2.05M1.86M
Interest Expense167K162K335K561K663K
Other Income / Expenses(2.3M)(11.86M)8.97M(10.78M)1.57M
Income Before Tax(13.52M)(19.52M)(6.53M)(30.16M)(23.71M)
Pre-Tax Margin-56.9%-73.7%-35.0%-149.2%-139.8%
Income Tax Expense27K78K185K61K169K
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Net Margin-57.0%-74.0%-35.9%-149.5%-140.8%
EPS (Basic)(3.48)(3.93)(0.75)(3.03)(2.10)
EPS (Diluted)(3.48)(3.93)(0.75)(3.03)(2.10)
Weighted Avg Shares3.89M4.99M9.01M9.96M11.38M
Weighted Avg Shares (Diluted)3.89M4.99M9.01M9.96M11.38M

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.